Independent Subtype of Idiopathic Multicentric Castleman Disease Defined
By LabMedica International staff writers Posted on 08 Nov 2022 |
Multicentric Castleman disease (MCD) comprises a heterogeneous group of rare disorders that exhibit generalized symptoms such as swelling of lymph nodes, anemia, fever, and fatigue. Idiopathic multicentric Castleman disease (iMCD) is a type of Castleman disease that is not related to KSHV/HHV8 infection.
KSHV/HHV8-negative MCD without association with the POEMS (polyneuropathy, organomegaly, endocrinopathy, M proteins, and skin changes) syndrome are termed “idiopathic,” i.e., diseases with no identifiable cause, and are thus referred to as “iMCD”. At present, specific clinical manifestations or diagnostic criteria have not been identified for iMCD, which often results in treatment delay.
Molecular Hematopathologists at the Okayama University Hospital (Okayama, Japan) and their colleagues analyzed lymph node specimens derived from 42 Japanese patients with lymph node involvement of iMCD not otherwise specified (iMCD-NOS), who met the consensus diagnostic criteria of iMCD and were negative for KSHV/HHV8 infections. Upon further examination, the team classified 34 of the 42 patients as the idiopathic plasmacytic lymphadenopathy (IPL) group and the remaining eight as the non-IPL group.
All lymph node specimens were fixed in 10% formalin and embedded in paraffin. Paraffin-embedded tissue blocks were sliced into 3 µm thin sections and stained with hematoxylin and eosin (H&E), immunohistochemical staining and Berlin blue staining. Immunohistochemical staining was performed using an automated BOND-III instrument (Leica Biosystems, Wetzlar, Germany) with the primary antibody of HHV-8, CD138, and α-SMA. In situ hybridization was also performed for the κ and λ light chains (Leica Biosystems).
The investigators reported that on grading histological features such as vascularity, plasmacytosis (high proportion of plasma cells), atrophic and hyperplastic germinal centers (GCs), they identified significant pathological differences between the specimens of the IPL and non-IPL groups. The IPL group demonstrated greater plasmacytosis and hyperplastic GCs compared to the non-IPL group. Conversely, the vascularity of the non-IPL group was higher than that of the IPL group. Clinically, the IPL group exhibited higher platelet count and serum antibody (immunoglobulin G) levels, with lesser fluid retention in pleural and/or abdominal cavity. The frequency of disease-specific autoantibody detection was also different between the groups.
The authors concluded that their results suggest that IPL is clinicopathologically a uniform disease entity, and may be an independent subtype of iMCD. Future studies are warranted to identify diagnostics, treatment, and follow-up plans that are specific to IPL. Given the heterogeneity of the non-IPL cases, clinicians are urged to identify a primary etiology of such cases, including atypical autoimmune diseases. These cases may benefit from molecular analysis to clarify underlying pathology. The study was originally published on September 7, 2022 in the International Journal of Molecular Science.
Related Links:
Okayama University Hospital
Leica Biosystems
Latest Hematology News
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
- First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
- POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
- First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
- Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections
- Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells
- Automated Hematology Platform Offers High Throughput Analytical Performance
- New Tool Analyzes Blood Platelets Faster, Easily and Accurately
- First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC
- Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals
- True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Blood Test Could Predict Outcomes in Emergency Department and Hospital Admissions
- Novel Technology Diagnoses Immunothrombosis Using Breath Gas Analysis
- Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour
- Unique AI-Based Approach Automates Clinical Analysis of Blood Data